Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
822
datasets available to search
ShareScore release 0.9.0
Dataset results
822 results for “monoclonal antibodies”
Data from: Blockade of dengue virus transmission from viremic blood to Aedes aegypti mosquitoes using human monoclonal antibodies
Background <p class="CxSpFirst">Dengue is the most prevalent arboviral disease of humans. Virus neutralizing antibodies are likely to be critical for clinical immunity after vaccination or natural infection. A number of human monoclonal antibodies (mAbs) have previously been characterized as able to neutralize the infectivity of dengue virus (DENV) for mammalian cells in cell-culture systems.</p> <p class="CxSpLast"> </p> Methodology/Principle findings <p class="CxSpFirst">We tested the capacity of 12 human mAbs, each of which had previously been shown to neutralize DENV in cell-culture systems, to abrogate the infectiousness of dengue patient viremic blood for mosquitoes. Seven of the twelve mAbs (1F4, 14c10, 2D22, 1L12, 5J7, 747(4)B7, 753(3)C10), almost all of which target quaternary epitopes, inhibited DENV infection of <i>Ae. aegypti</i>. The mAbs 14c10, 747(4)B7 and 753(3)C10 could all inhibit transmission of DENV in low microgram per mL concentrations. An Fc-disabled variant of 14c10 was as potent as its parent mAb.</p> <p class="CxSpLast"> </p> Conclusions/Significance <p class="CxSpFirst">The results demonstrate that mAbs can neutralize infectious DENV derived from infected human cells, in the matrix of human blood. Coupled with previous evidence of their ability to prevent DENV infection of mammalian cells, such mAbs could be considered attractive antibody classes to elicit with dengue vaccines, or alternatively, for consideration as therapeutic candidates.</p>
Peptide Mass Fingerprint Library of Monoclonal Murine anti-SARS-CoV-2 Antibodies
<p>The dataset contains fingerprints of monoclonal antibodies that can be used to identify the antibodies by using the open-source software ABID 2.0 <a href="https://bam.de/ABID">https://bam.de/ABID</a><br> More information can be found in the publication where this data was used to rapidly distinguish between 35 monoclonal murine Anti-SARS-CoV-2 antibodies: <a href="https://doi.org/10.3390/antib11020027">https://doi.org/10.3390/antib11020027 </a></p>
Risk of bias assessments for the Cochrane review 'SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19'
<p>Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review: SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.</p>
Risk of bias assessments for the Cochrane review 'SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19'
<p>Risk of bias assessments and support for judgement with ROB 2 tool for the Cochrane Review: SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.</p>
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
ClinicalTrials.gov study NCT04419467. IPD Sharing: YES. Countries: 6. Publications: 1.
Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults
ClinicalTrials.gov study NCT05118386. IPD Sharing: YES. Countries: 1. Publications: 3.
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
ClinicalTrials.gov study NCT01084252. IPD Sharing: YES. Countries: 17. Publications: 2.
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
ClinicalTrials.gov study NCT04776018. IPD Sharing: YES. Countries: 2. Publications: 1.
Data from: Blockade of dengue virus transmission from viremic blood to Aedes aegypti mosquitoes using human monoclonal antibodies
Open the record for dataset details and reuse information.
PfRH5-induced human monoclonal antibodies show broadly neutralizing activity in P. falciparum clinical isolates
<p>Vaccines to the <em>Plasmodium falciparum </em>reticulocyte binding-like protein homolog 5 (PfRH5) target the blood stage of the parasite's life cycle. PfRH5 has the potential to trigger the production of strain-transcendent antibodies and has proven its efficacy both in pre-clinical and early clinical studies. Vaccine-induced monoclonal antibodies (mAbs) to PfRH5 showed promising outcomes in cultured <em>P. falciparum </em>strains from distinct geographic areas. Here, we assessed the functional impact of vaccine-induced mAbs to PfRH5 on the genetically more complex <em>P. falciparum </em>clinical isolates. We used mAbs isolated from single-cell sorted B-cells of volunteers enrolled in the phase 1a (NCT02181088) clinical trial of the viral-vectored PfRH5 vaccine and used ex-vivo growth inhibition assays (GIA) to assess their efficacy in <em>P. falciparum </em>clinical isolates. Next-generation sequencing (NGS) was used to assess the breadth of genetic diversity in <em>P. falciparum </em>clinical isolates and to infer the genotype/phenotype relationship involved in antibody susceptibility. We showed a dose-dependent inhibition of clinical isolates with three main GIA groups, high, medium, and low. Except for one isolate, our data shows no significant differences in antibody GIA profile between the <em>P. falciparum </em>clinical isolates and the 3D7 reference strain, which harbours the vaccine allele. We observed an additive relationship, where the combination of GIA-low and GIA-medium antibodies resulted in increased GIA activities, having important implications for the contribution of specific monoclonal antibodies in polyclonal IgG responses. While our NGS analysis showed the occurrence of novel mutations in the <em>pfrh5 </em>gene, these mutations were predicted to have little or no functional impact on the antigen's structure or recognition by known mAbs. Our present findings complement earlier reports on the strain transcendent potential of mAbs to PfRH5 and constitute, to our knowledge, the first report on the susceptibility of <em>P. falciparum </em>clinical isolates from natural infections to vaccine-induced mAbs to PfRH5.</p>
Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study
<p>Background: Monoclonal antibodies (mAbs) against calcitonin gene-related peptides (CGRP) are novel treatments for migraine prevention. Based on a previous functional imaging study which investigated the CGRP receptor mAb (erenumab), we hypothesized that (i) the CGRP ligand mAb galcanezumab would alter central trigeminal pain processing; (ii) responders to galcanezumab treatment would show specific hypothalamic modulation in contrast to non-responders; and (iii) the ligand and the receptor antibody differ in brain responses.</p> <p>Methods: Using an established trigeminal nociceptive functional magnetic imaging paradigm, 26 migraine patients were subsequently scanned twice: before and 2–3 weeks after administration of galcanezumab.</p> <p>Results: We found that galcanezumab decreases hypothalamic activation in all patients and that the reduction was stronger in responders than in non-responders. Contrasting erenumab and galcanezumab showed that both antibodies activate a distinct network. We also found that pre-treatment activity of the spinal trigeminal nucleus (STN) and coupling between the STN and the hypothalamus covariates with the response to galcanezumab.</p> <p>Conclusions: These data suggest that despite relative impermeability of the blood-brain barrier for CGRP mAb, mAb treatment induces certain and highly specific brain effects which may be part of the mechanism of their efficacy in migraine treatment.</p> <p>Funding: This work was supported by the German Ministry of Education and Research (BMBF) of ERA-Net Neuron under the project code BIOMIGA (01EW2002 to AM) and by the German Research Foundation (SFB936-178316478-A5 to AM). The funding sources did not influence study conduction in any way. </p> <p>Clinical trial number: The basic science study was preregistered in the Open Science Framework (https://osf.io/m2rc6).</p>
Monoclonal antibodies from humans with Mycobacterium tuberculosis exposure or latent infection recognize distinct arabinomannan epitopes
<p>The surface polysacharide arabinomannan (AM) and related glycolipid lipoarabinomannan (LAM) play critical roles in tuberculosis pathogenesis. Human antibody responses to AM/LAM are heterogenous and knowledge of reactivity to specific glycan epitopes at the monoclonal level is limited, especially in individuals who can control <i><span>M. tuberculosis</span></i> infection<span>. </span>We generated human IgG mAbs to AM/LAM from B cells of two asymptomatic individuals exposed to or latently infected with <i><span>M. tuberculosis</span></i>. We here show that two of these mAbs have high affinity to AM/LAM, are non-competing, and recognize different glycan epitopes <span>distinct from other anti-AM/LAM mAbs reported. Both mAbs recognize virulent </span><i><span>M. tuberculosis</span></i><span> and nontuberculous mycobacteria with marked differences, can be used for the detection of urinary LAM, and can detect </span><i><span>M. tuberculosis</span></i><span> and LAM in infected lungs. These mAbs enhance our understanding of the spectrum of antibodies to AM/LAM epitopes </span>in humans <span>and</span> are valuable for <span>tuberculosis</span> diagnostic and research applications.</p>
Adaptive, randomized, non-inferiority trial to evaluate the efficacy of monoclonal antibodies in outpatients with mild or moderate COVID-19
<p><span>The dataset is based on the results of a trial called MANTICO (Clinical trial number NCT05205759). The study is a non-inferiority randomised controlled trial comparing the clinical efficacy of bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab in outpatients aged 50 or older with early COVID-19. The primary outcome was COVID-19 progression (hospitalisation, need of supplemental oxygen therapy, or death through day 14). </span></p>
Parameter estimation and identifiability analysis for a bivalent analyte model of monoclonal antibody-antigen binding
<p>Data for non-regenerative bivalent analyte binding interaction between CH505 transmitted founder gp120 and CH31 monoclonal antibody, an HIV-1 mAb with CD4-binding site specificity.</p> <p>This data set is submitted as part of the manuscript titled "Parameter estimation and identifiability analysis for a bivalent analyte model of monoclonal antibody-antigen binding"</p>
Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults
ClinicalTrials.gov study NCT03565315. IPD Sharing: NO. Countries: 1. Publications: 3.
Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)
ClinicalTrials.gov study NCT05877508. IPD Sharing: NO. Countries: 1. Publications: 1.
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS
ClinicalTrials.gov study NCT01300572. IPD Sharing: Not stated. Countries: 1. Publications: 1.
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or
ClinicalTrials.gov study NCT04693234. IPD Sharing: YES. Countries: 8. Publications: 1.
Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis
ClinicalTrials.gov study NCT02296775. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
ClinicalTrials.gov study NCT03111732. IPD Sharing: NO. Countries: 1. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.